Stopping Prometrium: What the Evidence Supports

Editorial evidence status: This page was reconciled to the current Prometrium label, The Menopause Society's current hormone-therapy materials, and direct discontinuation trials on August 29, 2026. Medical review is pending. It does not prescribe an individualized taper.

First Identify the Regimen You Are Actually Stopping

“Prometrium” can describe the same capsule used for very different purposes. The consequences of changing a finite amenorrhea course, a cyclic endometrial-protection regimen, a continuous menopause regimen, or a fertility protocol are not interchangeable.

The current Prometrium label covers two uses: prevention of endometrial hyperplasia in a postmenopausal woman with a uterus who is taking conjugated estrogens, and treatment of secondary amenorrhea [1]. Other uses, estrogen products, routes, and compounded progesterone preparations may involve different evidence and instructions.

Prometrium Stop-Decision and Coverage Matrix

This matrix is a triage tool, not a dosing schedule. Its main value is showing which facts change the decision before anyone invents a taper.

What the Current Prometrium Label Does—and Does Not—Say

The July 2026 DailyMed label gives two finite or cyclic schedules [1]:

• 200 mg at bedtime for 12 sequential days per 28-day cycle for labeled endometrial protection with daily conjugated estrogen; and
• 400 mg at bedtime for 10 days for secondary amenorrhea.

The label does not instruct patients to step from 200 mg to 100 mg, alternate nights, use every-third-night dosing, or taper for 4 to 12 weeks. It also does not describe a Prometrium dependence syndrome or give fixed timelines for insomnia, anxiety, mood change, or weight change after stopping.

The fact that labeled regimens include planned stopping points does not mean every patient should stop without guidance. It means a universal taper cannot be inferred from the capsule strength or from the word “hormone.” The indication and accompanying estrogen matter more.

What Menopause Discontinuation Trials Actually Studied

The Menopause Society says there are few studies on the best way to stop hormone therapy, that vasomotor symptoms recur in about half of women after discontinuation, and that direct comparative data are limited even though clinicians often advise gradual dose reduction [2]. That statement addresses menopausal hormone therapy as a whole; it is not a tested Prometrium-only taper.

Three randomized trials help define the boundary:

These trials do not prove that tapering is useless for every individual. They show that “a taper prevents withdrawal” is too strong, and they do not support one universal calendar. A slower reduction may be chosen to observe symptom recurrence or patient preference, but that is different from claiming that Prometrium physiologically requires a taper.

Endometrial Coverage Is a Separate Question From Withdrawal Symptoms

For a postmenopausal person with a uterus taking systemic estrogen, progesterone may be present to reduce estrogen-associated endometrial hyperplasia risk. The current label says this directly [1]. ACOG likewise explains that people with a uterus generally need a progestin with systemic estrogen to reduce uterine-cancer risk [6].

The PEPI endometrial trial makes the distinction concrete. In 596 postmenopausal participants followed for three years, conjugated estrogen alone produced substantially more simple, complex, and atypical hyperplasia than placebo. Regimens adding a progestogen—including cyclic micronized progesterone—had hyperplasia rates similar to placebo [7].

That is evidence for adequate coverage over time, not evidence that a single late or missed capsule creates an immediate quantified injury. Before stopping Prometrium while estrogen continues, resolve the replacement regimen, its start date, and whether it is appropriate for the estrogen dose and route. Do not fill that gap with an over-the-counter cream based on a generic equivalence claim.

Withdrawal Bleeding Is Not the Same as Drug Withdrawal

The label documents bleeding after a planned progesterone course in secondary amenorrhea. In one small study, 80% of 20 women receiving 300 mg daily for 10 days had withdrawal bleeding within seven days of the last dose; other labeled studies also measured bleeding after finite courses [1].

That finding has a narrow meaning: progesterone withdrawal can trigger endometrial shedding in an estrogen-primed amenorrhea population. It does not establish that 60% to 80% of all menopause patients bleed after stopping, that everyone bleeds within one week, or that absence of bleeding automatically requires an ultrasound. It also does not prove benzodiazepine-like dependence.

Bleeding expectations depend on menopausal status, uterine status, baseline cycle pattern, estrogen exposure, and the prescribed regimen. New postmenopausal bleeding, heavy bleeding, or persistent/recurrent unexpected bleeding should be assessed by a clinician rather than timed against a universal internet rule [1,8].

Discontinuation Preparation Record

Bring this record to the prescriber or pharmacist. It turns “How do I stop?” into a reproducible medication-reconciliation question:

• exact product name, manufacturer, strength, route, and whether it is compounded;
• indication: endometrial protection, secondary amenorrhea, fertility, sleep-related off-label use, or another reason;
• uterus present, hysterectomy, or uncertain;
• every estrogen product that will continue, including route, dose, and schedule;
• current Prometrium pattern: daily, cyclic, finite course, or another schedule;
• last dose taken and any missed doses;
• reason for changing treatment;
• prior bleeding pattern and any current unexpected bleeding;
• symptoms the hormone regimen was treating;
• proposed replacement progestogen and its start date, if estrogen continues; and
• pregnancy possibility, fertility-clinic involvement, clot symptoms, or sudden visual symptoms.

This record is more useful than choosing “cold turkey” or “taper” before the indication is known.

Missed Doses and Cyclic Off-Days

A planned off-day in a prescribed cyclic regimen is not the same as an accidental missed dose. A missed dose also is not evidence that a person should double the next dose, restart a course, or build an improvised taper. Use the current pharmacy label and contact the prescriber or pharmacist when the instruction is unclear—especially when systemic estrogen continues or the medication is part of fertility care.

When the Label Calls for Urgent Action

The Prometrium label says estrogen-plus-progestin therapy should be discontinued immediately if deep-vein thrombosis, pulmonary embolism, stroke, or myocardial infarction occurs or is suspected. It also directs discontinuation pending examination for sudden partial or complete vision loss or sudden onset of proptosis, double vision, or migraine, with permanent discontinuation if papilledema or retinal vascular lesions are found [1].

Those are urgent evaluation pathways, not situations in which a slow home taper should delay care. Chest pain, sudden shortness of breath, one-sided weakness, new speech difficulty, severe leg swelling, or sudden vision loss warrants emergency assessment.

Claims Removed From the Previous Page

The previous version supplied 4-to-12-week and every-other-night taper schedules without a source that tested them. It described receptor-level dependence, compared stopping to benzodiazepine withdrawal, assigned fixed percentages and timelines to bleeding and mood symptoms, recommended melatonin doses, predicted one-to-three-pound water loss, and gave unverified drug-interaction consequences after stopping.

It also treated combined hormone-therapy studies, animal neurosteroid research, and off-label vaginal progesterone data as if they established a Prometrium discontinuation protocol. Those claims were removed. The replacement page preserves the useful URL and its 201 Google clicks and 12,223 impressions while making the evidence boundaries visible.

Bottom Line

There is no label-approved universal Prometrium taper. If systemic estrogen will continue and the uterus is present, the central task is maintaining an appropriate endometrial-protection plan—not selecting arbitrary capsule intervals. If the entire menopause regimen is ending, tapering may be chosen for observation or preference, but randomized evidence has not shown a consistent longer-term symptom advantage. Finite amenorrhea courses, fertility protocols, urgent adverse events, compounded preparations, and off-label uses each require their own plan.